These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 2932585)
41. Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432. Hironaka K; Yamaguchi Y; Okita R; Okawaki M; Nagamine I Anticancer Res; 2006; 26(5B):3701-7. PubMed ID: 17094388 [TBL] [Abstract][Full Text] [Related]
42. Interference of the induction of suppressor cells by a streptococcal preparation, OK-432 through the blocking of suppressor inducer T-cells. Toge T; Kuroi K; Baba N; Kegoya Y; Takayama T; Yanagawa E Int J Immunopharmacol; 1990; 12(1):107-12. PubMed ID: 1689278 [TBL] [Abstract][Full Text] [Related]
43. [Antitumor activity of neutrophils induced by a nonspecific immunopotentiator OK-432. II. Experimental study using human malignant ascites]. Umemoto T; Saji S; Oonishi A; Kunii Y; Goshima H; Tachibana S; Takao H; Tanemura H; Sakata K Nihon Gan Chiryo Gakkai Shi; 1988 Jul; 23(7):1512-7. PubMed ID: 3183459 [No Abstract] [Full Text] [Related]
44. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice. Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841 [TBL] [Abstract][Full Text] [Related]
45. Immunological parameters in gastric cancer patients treated with immunotherapy of streptococcal preparation OK-432. Hanaue H; Nomoto S; Kimura T; Kutsuna T; Takeuchi T; Yoshizaki S Keio J Med; 1982 Dec; 31(4):159-68. PubMed ID: 6985379 [No Abstract] [Full Text] [Related]
46. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes]. Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027 [TBL] [Abstract][Full Text] [Related]
47. [Intratumor injection of OK-432-stimulated peripheral blood mononuclear cells: a significance of mononuclear cell-producing tumor inhibitory factor induced by OK-432]. Mizoguchi T; Katano M; Yamamoto H; Hisatsugu T Nihon Geka Gakkai Zasshi; 1987 Jun; 88(6):794. PubMed ID: 3627102 [No Abstract] [Full Text] [Related]
48. [Effect of intratumoral injection of the mixture of OK-432 and fibrinogen (OK/fbg) on gastric cancer]. Takeda T; Wakasugi T; Katsumoto Y; Sakita I; Nagaoka H; Morimoto H; Tsujinaka T; Monden T; Shiozaki H; Shimano T Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1458-60. PubMed ID: 1530293 [TBL] [Abstract][Full Text] [Related]
49. [Endoscopic preoperative intralesional injection of OK-432 in early gastric cancer]. Yamane T; Sagara Y; Suzuki G; Kasuga M; Sakita M; Fujita Y; Majima S Gan To Kagaku Ryoho; 1984 Apr; 11(4):930-4. PubMed ID: 6721507 [TBL] [Abstract][Full Text] [Related]
50. [The effect of OK-432 in the treatment of primary lung cancer]. Kishimoto T; Okada K Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430 [TBL] [Abstract][Full Text] [Related]
51. [Management of malignant ascites with a streptococcal preparation, OK-432: induction of growth inhibition factor(s) against tumor cells]. Katano M; Yamamoto H; Hisatsugu T Nihon Geka Gakkai Zasshi; 1986 Apr; 87(4):471. PubMed ID: 3713694 [No Abstract] [Full Text] [Related]
52. [Influence of OK 432 upon postoperative alteration in activities producing lymphokines, IL 1, IL 2, and IFN, of peripheral blood mononuclear cells derived from patients with gastric cancer]. Hosoi J Nihon Gan Chiryo Gakkai Shi; 1987 Apr; 22(3):603-13. PubMed ID: 2443588 [No Abstract] [Full Text] [Related]
53. [The influence of a biological response modifier on thoracic lymphocytes--a study involving clinical cases and animal experiments]. Hanaue H; Kurosawa T; Miyakawa S; Kitano Y; Nemoto A; Yamoto H; Asagoe T; Shikata J Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1285-9. PubMed ID: 3488025 [TBL] [Abstract][Full Text] [Related]
54. [A case of recurrence of gastric cancer with an abdominal wall tumor responding to intratumoral OK-432 administration]. Saeki T; Kuninobu H; Niimoto M; Hattori T; Ohoya M; Yoshida H; Sata H; Kajitani Y Gan No Rinsho; 1987 Apr; 33(4):417-20. PubMed ID: 2952818 [TBL] [Abstract][Full Text] [Related]
55. Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer. Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tobe T Biotherapy; 1990; 2(3):213-22. PubMed ID: 2206774 [TBL] [Abstract][Full Text] [Related]
56. [Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer]. Nio Y; Tobe T Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1436-8. PubMed ID: 2586435 [TBL] [Abstract][Full Text] [Related]
57. [Experimental study on the antitumor activity of regional lymph nodes during immunotherapy]. Kawata H Nihon Geka Gakkai Zasshi; 1984 Nov; 85(11):1479-89. PubMed ID: 6521727 [TBL] [Abstract][Full Text] [Related]
58. [The effect of intraperitoneal administration of OK-432 with recombinant interleukin-2 to patients with peritonitis carcinomatosa of recurrent gynecological cancer and changes in ascitic lymphocyte subsets]. Kanaoka Y; Umesaki N Nihon Sanka Fujinka Gakkai Zasshi; 1991 May; 43(5):489-96. PubMed ID: 2056223 [TBL] [Abstract][Full Text] [Related]
59. [Antitumor effect of intraperitoneal administration of a streptococcal preparation, OK-432, in carcinomatous peritonitis. I. Experimental study in the rat]. Saji S; Miya K; Oshita H; Nonomura O; Yokoyama Y; Yamamoto S; Takekoshi T; Sakata K Gan To Kagaku Ryoho; 1982 Nov; 9(11):1961-8. PubMed ID: 7184383 [TBL] [Abstract][Full Text] [Related]